About Asana BioSciences
Asana BioSciences is a Healthcare company based in Lawrenceville (United States) founded in 2014. Clinical-stage biopharmaceuticals for oncology and related diseases are developed. The company has 7 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ASANA BIOSCIENCES, LLC. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Asana BioSciences is clinical stage biopharma with a focus on oncology. Other therapeutic areas include pain, dermatology and autoimmune diseases. Asanas lead candidates, ASN001 and ASN002 are in Phase III clinical development. ASN001, a novel and highly selective CYP17 inhibitor that does not require prednisone co-administration, targets metastatic castration-resistant prostate cancer. ASN002 is a novel oral inhibitor of spleen tyrosine kinase (SYK) and Janus kinase (JAK), which is currently in Phase III studies in patients with non-Hodgkins lymphoma and solid tumors. Evaluation of ASN002 in autoimmune disease indications is also being planned. Both these programs are approaching the end of dose-finding phase of the trials, and Asana expects to announce initial safety and efficacy results in early 2007. ASN003 is a selective RAFPI3K inhibitor whose IND was accepted by FDA in Oct 2016. ASN004 is an antibody drug conjugate (ADC) targeting 5T4-oncofetal antigen that selectively and efficiently delivers a cytotoxic agent into tumor cells, resulting in selective anti-proliferative activity and complete tumor regression in multiple tumor models including breast, lung and colon. ASN007 is a novel ERK inhibitor that shows activity against multiple KRAS mutant driven tumor models. These programs will enter clinical development in 2H 2017.,
- Headquarters Lawrenceville, United States
- Employees 7
- SectorsHealthcare
- Website asanabiosciences.com
- Legal Name Asana Biosciences, Llc.
- Investors
- Employee Count7
Funding Insights of Asana BioSciences
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Asana BioSciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2014 | Seed | – | – |
1 investors in total: 1 institutional.
Investors in Asana BioSciences
Asana BioSciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Tarsadia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity are directed toward multiple sectors. | tarsadia.com | Newport Beach, United States |
Investor details for Asana BioSciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Asana BioSciences
2 dated milestones of Asana BioSciences, from founding to its latest funding, stage changes and deals.
- Founded Asana BioSciences is founded.
- Funding First funding round.
Competitors of Asana BioSciences
Asana BioSciences has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Asana BioSciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Asana BioSciences (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Asana Biosciences
Complete news archive for Asana BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Asana BioSciences
Asana BioSciences was founded in 2014.
Asana BioSciences is headquartered in Lawrenceville, United States.
Asana BioSciences has 7 employees.
Asana BioSciences is clinical stage biopharma with a focus on oncology. Other therapeutic areas include pain, dermatology and autoimmune diseases. Asanas lead candidates, ASN001 and ASN002 are in Phase III clinical development. ASN001, a novel and highly selective CYP17 inhibitor that does not require prednisone co-administration, targets metastatic castration-resistant prostate cancer. ASN002 is a novel oral inhibitor of spleen tyrosine kinase (SYK) and Janus kinase (JAK), which is currently in Phase III studies in patients with non-Hodgkins lymphoma and solid tumors. Evaluation of ASN002 in autoimmune disease indications is also being planned. Both these programs are approaching the end of dose-finding phase of the trials, and Asana expects to announce initial safety and efficacy results in early 2007. ASN003 is a selective RAFPI3K inhibitor whose IND was accepted by FDA in Oct 2016. ASN004 is an antibody drug conjugate (ADC) targeting 5T4-oncofetal antigen that selectively and efficiently delivers a cytotoxic agent into tumor cells, resulting in selective anti-proliferative activity and complete tumor regression in multiple tumor models including breast, lung and colon. ASN007 is a novel ERK inhibitor that shows activity against multiple KRAS mutant driven tumor models. These programs will enter clinical development in 2H 2017.,.
Asana BioSciences's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Asana BioSciences has 1 investor. Key investors include Tarsadia.
Asana BioSciences operates through Asana Biosciences, Llc..